Firmagon, the newly FDA approved gonadotropin-releasing hormone (GnRH) receptor blocker should perhaps be considered as a better alternative to the traditionally used ADT drugs like lupron and zoladex (GnRH agonists) which are the current standard of care.
Recent data released from the ongoing five-year Firmagon (degarelix) extension study (CS21a) has demonstrated the long term efficacy and tolerability in study patients with advanced hormone-dependent prostate cancer. This study supports using Firmagon as first-line androgen deprivation therapy. Details of this study were announced today at the European Association of Urology (EAU) 2011 Annual Meeting.
Firmagon is indicated for the treatment of men with advanced hormone-dependent prostate cancer. The extension study of the pivotal Firmagon vs. leuprorelin trial (CS21) was designed to collect extended safety and tolerability data. At the closure of the Phase III trial, all men participating were offered the option to receive Firmagon as part of the extension study. All men who elected to and received Firmagon continued with their treatment